## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> RINGROSE PETER S						2. Issuer Name and Ticker or Trading Symbol <u>Theravance Biopharma, Inc.</u> [TBPH]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	ast) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2014								X Direct Office below	r (give title		10% Ov Other ( below)	
C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BLVD.						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SOUTH SAN FRANCISCO CA 94080													X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	Sity) (State) (Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Execution Date,			Transaction Dispos Code (Instr. and 5)		urities Acquired (A sed Of (D) (Instr. 3,		Securit Benefic Owned	ties cially	6. Own Form: I (D) or Indirec	Direct	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amoun	unt (A) or (D) P		1		(Instr. /	4)	(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transact Code (In 8)				6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	Ov Fo Di or (l) 4)	vnership rm: rect (D) Indirect (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$23.51	06/03/2014			A		12,000		(1)	06	/02/2024	Common Stock	12,000	\$0	12,000		D	
Stock Option (Right to Buy)	\$23.51	06/03/2014			Α		12,000		(2)	06	/02/2024	Common Stock	12,000	\$0	12,000		D	

## Explanation of Responses:

1. This option may be exercised and shall be vested as to 1/36th of the shares subject to this option when optionee completes each continuous month of service following the grant date.

2. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.